Received Apr 9, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | UNK | A5T73 | — |
only the adjuvant portion of the Shingrix vaccine was administered to a patient.; only the adjuvant portion of the Shingrix vaccine was administered to a patient.; This non-serious case was reported by a nurse via call center representative and described the occurrence of inappropriate preparation of medication in a 52-year-old female patient who received Herpes zoster (Shingrix) (batch number A5T73, expiry date 28-MAR-2027) for prophylaxis. On 28-MAR-2025, the patient received Shingrix. On 28-MAR-2025, an unknown time after receiving Shingrix, the patient experienced inappropriate preparation of medication (Verbatim: only the adjuvant portion of the Shingrix vaccine was administered to a patient.) and inappropriate dose of vaccine administered (Verbatim: only the adjuvant portion of the Shingrix vaccine was administered to a patient.). The outcome of the inappropriate preparation of medication and inappropriate dose of vaccine administered were not applicable. Additional Information: GSK Receipt Date: 28-MAR-2025 The nurse reported that the adjuvant portion of the Shingrix vaccine was administered to a patient, which led to inappropriate preparation of medication and inappropriate dose of vaccine administered. The vaccine administration facility was the same as primary reporter.